NCT03035630 - Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Biotech Hunter

Timeline

Start Date

May 23, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2020

Conditions

Clear-cell Renal Cell CarcinomaRCCKidney CancerClear-cell Kidney Carcinoma

Interventions

DRUG

Avelumab

Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle

DRUG

Sunitinib

Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle

Trial Locations (1)

University of Alabama Hematology Oncology Clinic at Medical West, Birmingham